The book is currently out of stock
More about the book
The study investigates the surge in mergers and acquisitions within the pharmaceutical industry, highlighting over 1,300 deals valued at approximately US$ 690 billion from 2000 to 2009. It emphasizes the largest transaction during this period, Pfizer's acquisition of Wyeth for US$ 66.7 billion in 2009. The research explores the motivations behind these significant mergers, particularly as responses to patent expirations, and examines their implications for drug innovation, reflecting on the broader public interest surrounding these transactions.
Book purchase
Do Pharmaceutical Mergers Harm Drug Innovation?, Jan-Hinrik Schmidt
- Language
- Released
- 2015
- product-detail.submit-box.info.binding
- (Paperback)
We’ll notify you via email once we track it down.
Payment methods
- Title
- Do Pharmaceutical Mergers Harm Drug Innovation?
- Language
- English
- Authors
- Jan-Hinrik Schmidt
- Publisher
- GRIN Verlag
- Released
- 2015
- Format
- Paperback
- Pages
- 56
- ISBN13
- 9783656962175
- Category
- Business and Economics
- Description
- The study investigates the surge in mergers and acquisitions within the pharmaceutical industry, highlighting over 1,300 deals valued at approximately US$ 690 billion from 2000 to 2009. It emphasizes the largest transaction during this period, Pfizer's acquisition of Wyeth for US$ 66.7 billion in 2009. The research explores the motivations behind these significant mergers, particularly as responses to patent expirations, and examines their implications for drug innovation, reflecting on the broader public interest surrounding these transactions.